Ascension Providence Hospitals - Southfield

Summary

Ascension Providence Hospitals - Southfield is a medical facility located in Southfield, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Multiple Myeloma and other specialties. Ascension Providence Hospitals - Southfield is involved with conducting 235 clinical trials across 312 conditions. There are 10 research doctors associated with this hospital, such as Adam M. Forman, Susan E. Lyons, Cynthia M. Vakhariya, and Howard R. Terebelo.

Top PIs

Clinical Trials running at Ascension Providence Hospitals - Southfield

Multiple Myeloma

Breast Cancer

Esophageal cancer

Heart Failure

Non-Small Cell Lung Cancer

Pancreatic Carcinoma

Breast cancer

Gastric cancer

Lung Cancer

Pancreatic Cancer

Ide-cel + Lenalidomide

for Multiple Myeloma

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Recruiting

2 awards

Phase 3

1 criteria

Talquetamab Combinations

for Multiple Myeloma

This trial is testing two new drug combinations to treat multiple myeloma. The combinations include talquetamab with either pomalidomide or teclistamab. These drugs help the immune system better identify and destroy cancer cells. The goal is to see if these new combinations work better than existing treatments.

Recruiting

2 awards

Phase 3

5 criteria

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria